Dr Hurvitz speaks with ecancertv at SABCS 2016 about the outcomes of the neoMONARCH trial of abemaciclib, a CDK 4/6 inhibitor, in combination with anastrozole for women with HR positive breast cancer.
The study found that, alone or with anastrozole, abemaciclib induced significantly greater cell cycle arrest, defined by reduced Ki67 expression.
These results were first presented at a press conference session, with video available here.
Dr Hurvitz spoke more on CDK4/6 inhibition at an ecancer symposium in Copenhagen, here.
Supported by a grant from Pfizer Inc.